Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsRenvela

    Renvela

    Jump to

    • Regulatory claims on Agila settled, says Strides Shasun

      There was some regulatory overhangs post Strides-Mylan Agila transaction, says Arun Kumar, Executive VC & MD of Strides Shasun.

    • Lupin falls 2% on Credit Suisse downgrade to underperform

      Credit Suisse feels Lupin is trading at high end of historical valuations (23x FY18 EPS) and has low margin of safety with high concentration risk.

    • Lupin Q3 profit seen down 18% to Rs 493 cr, US biz may hit

      Revenue is seen rising 7.3 percent to Rs 3,375.6 crore in quarter ended December 2015 compared to Rs 3,144.9 crore in year-ago period, driven by domestic business but impacted by US business.

    • Lupin up 4%; Credit Suisse upgrades, bets on diabetes drugs

      Lupin has taken 200 percent price increase in Fortamet, according to Price Rx. The brokerage says it has been highlighting this opportunity for Lupin after a 8 times price increase in competing product Glumetza.

    • Lupin plunges 5%, Nomura downgrades to neutral, cuts target

      Shares of Lupin fell 4.7 percent intraday Friday (in addition to 2.5 percent decline in previous session) after the brokerage Nomura downgraded the stock to neutral, citing slower US sales growth. Target price reduced to Rs 1,661 from Rs 1,738.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347